A tumor under the fluorescence microscope: the tissue of this pancreatic tumor in a mouse glows green, the nanoparticles orange.
Newswise — The method promises to treat pancreatic carcinomas with more accuracy and with fewer side effects than current cancer therapies. Using so-called nanoparticles, they transported the active substance Gemcitabine in large quantities directly into the tumor.
“Targeting the drug in high concentrations into the tumor cells with the help of the nanoparticles increases the efficacy and spares healthy cells. This can reduce the severe side effects that occur with Gemcitabine,” explains Myrto Ischyropoulou, lead author of the study recently published in the journal Advanced Materials. “Currently, patients are given the free drug. This is distributed throughout the body and can lead to toxic effects in all parts of the body. The nanoparticles, on the other hand, release the drug mainly in the tumor.” Joanna Napp, scientist at the UMG and the MPI, adds: “Using imaging methods, we have already been able to demonstrate in mouse models that the nanoparticles accumulate in the tumors.”
The administration of nanoparticles also allows resistance mechanisms in the tumor to be circumvented. “Free Gemcitabine is often no longer taken up by the tumor very early on and is thus largely ineffective there. However, it still leads to considerable side effects, for example in the liver and kidneys,” explains Claus Feldmann from KIT. “By using a different uptake mechanism in tumor cells, our nanoparticles could be a very effective new therapeutic approach here.”
The research success is an excellent example of successful interdisciplinary cooperation, says Frauke Alves, group leader at the MPI and the UMG. “From the idea to the development of the new nanoparticles to preclinical testing, chemists, biologists, pharmacists, and physicians have worked hand in hand.” With a spin-off, the scientists are now working to bring their new nanoparticles out of the test phase and into clinical use as quickly as possible.
Further information:
Research Group „Translational Molecular Imaging“, Prof. Frauke Alves
Original Publication
Myrto Ischyropoulou, Kristina Sabljo, Leonie Schneider, Christof M. Niemeyer, Joanna Napp, Claus Feldmann, and Frauke Alves: High-Load Gemcitabine Inorganic-Organic Hybrid Nanoparticles as Image-Guided Tumor-Selective Drug-Delivery System to Treat Pancreatic Cancer. Advanced Materials, October 2023. DOI:10.1002/adma.202305151
https://onlinelibrary.wiley.com/doi/10.1002/adma.202305151
Being “The Research University in the Helmholtz Association”, KIT creates and imparts knowledge for the society and the environment. It is the objective to make significant contributions to the global challenges in the fields of energy, mobility, and information. For this, about 9,800 employees cooperate in a broad range of disciplines in natural sciences, engineering sciences, economics, and the humanities and social sciences. KIT prepares its 22,300 students for responsible tasks in society, industry, and science by offering research-based study programs. Innovation efforts at KIT build a bridge between important scientific findings and their application for the benefit of society, economic prosperity, and the preservation of our natural basis of life. KIT is one of the German universities of excellence.
RSS